ID: ALA98195

Max Phase: Preclinical

Molecular Formula: C18H19NO4S

Molecular Weight: 345.42

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC(=O)c1ccc2c(c1)[C@H](NC(=O)c1ccsc1)[C@@H](O)C(C)(C)O2

Standard InChI:  InChI=1S/C18H19NO4S/c1-10(20)11-4-5-14-13(8-11)15(16(21)18(2,3)23-14)19-17(22)12-6-7-24-9-12/h4-9,15-16,21H,1-3H3,(H,19,22)/t15-,16+/m0/s1

Standard InChI Key:  WRTOKPSXGVEQHE-JKSUJKDBSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 345.42

Molecular Weight (Monoisotopic): 345.1035

AlogP: 2.95

#Rotatable Bonds: 3

Polar Surface Area: 75.63

Molecular Species: NEUTRAL

HBA: 5

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 5

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 12.47

CX Basic pKa:

CX LogP: 1.91

CX LogD: 1.91

Aromatic Rings: 2

Heavy Atoms: 24

QED Weighted: 0.84

Np Likeness Score: -0.19

References

1. Chan WN, Evans JM, Hadley MS, Herdon HJ, Jerman JC, Parsons AA, Read SJ, Stean TO, Thompson M, Upton N..  (1999)  Identification of (-)-cis-6-acetyl-4S-(3-chloro-4-fluoro-benzoylamino)- 3,4-dihydro-2,2-dimethyl-2H-benzo[b]pyran-3S-ol as a potential antimigraine agent.,  9  (2): [PMID:10021946] [10.1016/s0960-894x(98)00728-8]

Source

Source(1):

• Scientific Literature